[Federal Register Volume 71, Number 84 (Tuesday, May 2, 2006)]
[Notices]
[Pages 25851-25852]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-6548]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: (301) 496-7057; fax: (301) 402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Monoclonal Antibody for Lyme Disease Diagnostic and Research

Alan G. Barbour (NIAID)
HHS Reference No. E-075-2006/0--Research Materials
Licensing Contact: Susan Ano; 301/435-5515; [email protected]

    The hybridoma producing a monoclonal antibody against the major 
flagellin protein (FlaB) is available for licensing. This antibody can 
be used in diagnostic and research applications related to Lyme disease 
or other Borrelia-caused conditions. More information about this 
antibody can be found in Barbour et al., Infection and Immunity, May 
1986, volume 52(5), pages 549-554.

Broad Spectrum Antiviral Compounds

Gary J. Nabel and Jae Ouk Kim (NIAID)
U.S. Provisional Application No. 60/775,666 filed 21 Feb 2006 (HHS 
Reference No. E-013-2006/0-US-01)
Licensing Contact: Susan Ano; 301/435-5515; [email protected]

    This technology relates to broad spectrum antiviral compounds for 
treatment of infection caused by enveloped viruses. The compounds are 
fusions molecules of a phospholipase and a viral binding polypeptide. 
The subject technology requires the phospholipase component of the 
antiviral compound to have enzymatic activity, whereas previous studies 
demonstrating antiviral activity of some phospholipases did not require 
enzymatic activity. The compounds described by the current technology 
are not necessarily virus or viral strain specific, unlike many 
currently available antiviral compounds. The antiviral activity of the 
compounds has been demonstrated in vitro with representative viruses 
pseudotyped with envelope proteins from Ebola, HIV, Marburg, and VSV. 
Additionally, the antiviral activity was demonstrated with wild type 
HIV. The potential broad application of these compounds could address a 
significant health need for effective antivirals.
    The Vaccine Research Center at the National Institute of Allergy 
and Infectious Diseases is seeking statements of capability or interest 
from parties

[[Page 25852]]

interested in collaborative research to further develop, evaluate, or 
commercialize treatments or vaccines against infections caused by 
enveloped viruses. Please contact Anna Z. Amar at 301/451-3525 and/or 
[email protected] for more information.

Increased Cytokine Expression

Barbara Felber and George Pavlakis (NCI)
U.S. Provisional Application No. 60/758,819 filed 13 Jan 2006 (HHS 
Reference No. E-254-2005/0-US-01)
U.S. Provisional Application No. 60/758,680 filed 13 Jan 2006 (HHS 
Reference No. E-267-2005/0-US-01)
Licensing Contact: Susan Ano; 301/435-5515; [email protected]

    The current technologies describe optimization of the genes 
encoding interleukins 12 (IL-12) and 15 (IL-15), resulting in higher 
levels of protein expression. Cytokines play an important role in both 
innate and adaptive immune responses. Their utility as 
immunotherapeutics against infectious disease and cancer as well as 
vaccine adjuvants has been previously demonstrated. However, cytokine 
expression from native sequences can be sub-optimal for several 
reasons, including potential splice sites within RNA and low stability 
coding sequences. The current technologies offer a means to increase 
expression of these important molecules. In vitro studies show a 5- to 
10-fold mean increase in cytokine protein production. In some 
instances, further increased expression was achieved by use of a 
heterologous signal peptide. The subject technologies have application 
to DNA vaccination and treatment of diseases such as HIV, hepatitis B 
or C, cancer, and influenza. Some fields of use may not be available 
for licensing.

    Dated: April 24, 2006.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. E6-6548 Filed 5-1-06; 8:45 am]
BILLING CODE 4167-01-P